Number of Shares and Votes in Orexo
UPPSALA, Sweden--(BUSINESS WIRE)-- The number of shares and votes in Orexo AB (STO: ORX) has changed as a result of the exercise of warrants in connection with the company’s incentive programs.
Today, the last trading day of the month, there are in total 34,666,107 shares - whereof 34,531,107 are ordinary shares and 135,000 class C shares - and 34,544,607 votes in the company.
About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.
For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn. For further information about Zubsolv in the US, please visit www.zubsolv.com.
The information was submitted for publication at 6:00pm CET, September 30, 2016
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005700/en/
Orexo AB
Henrik Juuel,
EVP and CFO Lena Wange,
IR &
Communications Manager
Tel: 018 780 88 00
email: [email protected]
Source: Orexo
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HELIX Speaks: Learn Learn Learn Episode 17 Makes History as the First AI-Driven Episode, Official Website "HelixEngine.ai" Goes Live
- UPDATE: Rogers Sugar Announces Extention of Collective Agreement at Taber Refinery
- Shell to provide $5 million in disaster relief funding for Venezuela
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share